Owkin
Industry / private company
Location:
Paris,
France (FR)
AI allows pre-screening of FGFR3 mutational status using routine histology slides of muscle-invasive bladder cancer. (2024)
Bannier PA, Saillard C, Mann P, Touzot M, Maussion C, Matek C, Klümper N, et al.
Journal article
Response heterogeneity as a new biomarker of treatment response in patients with neuroendocrine tumors (2023)
Dromain C, Pavel ME, Ronot M, Schaefer N, Mandair D, Gueguen D, Cheng C, et al.
Journal article
The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumors: Results from phase 3 of the RAISE project (2021)
Pavel ME, Dromain C, Ronot M, Schaefer N, Mandair D, Gueguen D, Elvira D, et al.
Conference contribution
Dissociated response as a new biomarker of treatment response in neuroendocrine tumors: Results from phase 3 of the RAISE project (2021)
Dromain C, Pavel ME, Ronot M, Schaefer N, Mandair D, Gueguen D, Cheng C, et al.
Conference contribution